LEVOXYL — Class II drug recall D-0150-2017
Terminated recall by Pfizer Inc., reported 2016-11-30, distributed nationwide. Superpotent
| Recall number | D-0150-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2016-11-07 |
| Classified | 2016-11-23 |
| Reported by FDA | 2016-11-30 |
| Terminated | 2020-05-01 |
| Distributed | Nationwide (US) |
| Quantity | 2,666 bottles |
| Reason classes | potency |
| NDC | 60793-0850, 60793-0850-01, 60793-0850-10, 60793-0851, 60793-0851-01, 60793-0851-10, 60793-0852, 60793-0852-01, 60793-0852-10, 60793-0853, 60793-0853-01, 60793-0853-10, 60793-0854, 60793-0854-01, 60793-0854-10, 60793-0855, 60793-0855-01, 60793-0855-10, 60793-0856, 60793-0856-01, 60793-0856-10, 60793-0857, 60793-0857-01, 60793-0857-10, 60793-0858 and 8 more |
| Expiration dates | 2017-08 |
Product
LEVOXYL(R) (levothyroxine sodium tablets, USP), 200 mcg, 100 count bottles, Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620, NDC 60793-860-01
Reason for recall
Superpotent
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0150-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.